Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Mizuho Analyst Says

Biogen (NASDAQ:BIIB) had its price target increased by analysts at Mizuho from $207.00 to $236.00 in a report released on Tuesday, MarketBeat Ratings reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Mizuho’s price objective would suggest a potential upside of 23.43% from the stock’s current price.

A number of other equities analysts also recently weighed in on BIIB. HC Wainwright upped their target price on Biogen from $194.00 to $228.00 and gave the company a “buy” rating in a report on Monday. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Stifel Nicolaus lifted their target price on shares of Biogen from $202.00 to $214.00 and gave the company a “buy” rating in a research note on Friday, February 6th. Canaccord Genuity Group raised their price target on shares of Biogen from $220.00 to $230.00 and gave the company a “buy” rating in a report on Monday. Finally, Guggenheim lifted their price objective on shares of Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a research note on Monday. Thirteen analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $206.54.

Biogen Stock Performance

Biogen stock opened at $191.20 on Tuesday. The firm’s 50 day simple moving average is $177.65 and its 200-day simple moving average is $158.12. Biogen has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The company has a market cap of $28.06 billion, a P/E ratio of 21.70, a price-to-earnings-growth ratio of 1.50 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last released its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same quarter in the prior year, the company earned $3.44 earnings per share. The company’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities research analysts predict that Biogen will post 15.83 EPS for the current year.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.18% of the company’s stock.

Hedge Funds Weigh In On Biogen

A number of hedge funds have recently modified their holdings of BIIB. WPG Advisers LLC grew its position in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 117 shares during the period. First Horizon Corp acquired a new stake in shares of Biogen in the 4th quarter valued at $30,000. Root Financial Partners LLC grew its holdings in shares of Biogen by 198.4% in the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 123 shares during the last quarter. GoalVest Advisory LLC bought a new stake in shares of Biogen in the 4th quarter worth about $35,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of Biogen during the 2nd quarter worth about $25,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat FY‑2026 guidance — Biogen reported Q4 results that topped EPS and revenue expectations and provided FY‑2026 EPS guidance (15.25–16.25) that reassured investors about earnings power. This is a primary driver of recent price strength. Why Biogen Is Up After Earnings
• Positive Sentiment: Analyst upgrades and higher price targets — Several firms raised targets and reiterated buys after the results (examples: Mizuho, Goldman Sachs, Canaccord, Citigroup and others), supporting further upside sentiment. Mizuho Raises Price Target
• Positive Sentiment: Regulatory progress for Leqembi (lecanemab) — The BLA for a subcutaneous formulation of Leqembi received priority review, which could expand commercial reach and margins if approved. That helped sentiment around Biogen’s Alzheimer’s growth runway. Leqembi Subcutaneous Priority Review
• Neutral Sentiment: Board leadership change — Caroline Dorsa is retiring as Board Chair; Dr. Maria C. Freire was elected Chair effective immediately. Governance continuity reduces uncertainty but is unlikely to be a major near‑term price mover. Board Chair Transition
• Neutral Sentiment: Pipeline diversification updates — Advances in lupus and SMA programs improve long‑term optionality but will take time to drive revenue; these were noted by coverage but are not immediate catalysts. Pipeline Advances
• Neutral Sentiment: Short‑interest data appears inconsistent — Recent feeds reporting a “significant increase” actually show zero shares, so no clear short‑squeeze dynamics are evident from the available data. (internal short‑interest entries)
• Negative Sentiment: Insider selling — Senior insider Priya Singhal sold 2,660 shares (~$531k), which some investors interpret as a modest negative signal about near‑term insider conviction. Insider Form 4
• Negative Sentiment: Legacy franchise pressure and execution risks — Analysts caution that MS franchise erosion and the challenges of scaling Leqembi access/commercialization could limit upside and add execution risk. Franchise Pressure Analysis

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.